Internet-Based App for Breast Cancer Treatment Adherence
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify whether you need to stop taking your current medications. However, it focuses on improving adherence to endocrine therapy, so you will likely need to continue taking your prescribed endocrine therapy medications.
What data supports the effectiveness of the Internet-Based App for Breast Cancer Treatment Adherence?
Research shows that using a web-based app to manage symptoms and communicate with healthcare teams can improve adherence to breast cancer treatments by helping patients manage side effects better. Similar digital tools have been effective in increasing adherence to cancer therapies by providing reminders and facilitating communication with healthcare providers.12345
Is the Internet-Based App for Breast Cancer Treatment Adherence safe for humans?
How is the Internet-Based App for Breast Cancer Treatment Adherence different from other treatments?
The Internet-Based App for Breast Cancer Treatment Adherence is unique because it uses a digital platform to help patients manage symptoms and adhere to their medication schedule by providing real-time symptom reporting and reminders, which can be shared with healthcare providers for timely intervention.14689
What is the purpose of this trial?
This clinical trial looks at the use of an internet-based application (app) intervention in improving adherence to endocrine therapy (ET) among patients with early stage hormone receptor-positive HER2-negative breast cancer. ET can significantly reduce the return of the cancer in patients who are compliant with their treatment regimen. Despite this, adherence to ET is poor due to side effects, lack of social support and timely access to clinicians, and poor patient understanding of the necessity and effectiveness of the therapy. An internet-based app may help patients improve their adherence to ET by providing reminders, side effect mitigation strategies available in the educational videos and from contacting providers/ nurse on the research team directly via the app.
Research Team
Jane L Meisel
Principal Investigator
Emory University Hospital/Winship Cancer Institute
Eligibility Criteria
This trial is for adults over 18 with early-stage hormone receptor-positive, HER2-negative breast cancer who've finished recommended treatments and started on aromatase inhibitors or Tamoxifen within the last six months. Participants need internet access and must speak English.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive access to a web-based app for 3 months to improve adherence to endocrine therapy
Follow-up
Participants are monitored for adherence and satisfaction with the app and endocrine therapy
Treatment Details
Interventions
- Web Based App Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator